Research & Clinical Trials

This is a tool to identify specific Alzheimer’s clinical trials. Just click on the start button and enter the information as prompted. You will be provided with a list of the trials within your geographic area.

Clinical Trial Sites in New York City

These Alzheimer’s clinical trial sites in New York City welcome individuals with memory issues to make an appointment for evaluation. After screening and initial testing, for qualifying candidates the site will suggest appropriate trials for consideration.

Biovie Trials

BioVie is currently conducting a late-stage clinical trial whereby the first fully qualifying 320 patients with mild to moderate Alzheimer’s Disease may participate. Study participants will receive extensive medical testing and
treatments. Participants will have about a 50% (1 in 2) chance of receiving NE-3107 and about a 50% (1 in 2) chance of receiving placebo (an inactive capsule that looks like the NE-3107). The study is double-blind meaning that neither you nor the Study Doctor will know who is receiving NE-3107 or placebo. Study participants may be among the first people to have the chance to receive NE-3107, with its unique dual mechanism of action, while contributing to the advancement of medical understanding in treating Alzheimer’s.

Who is eligible to participate?

• People who are from 60 to 85 years of age at the beginning of their study participation
• Show medical evidence of mild to moderate Alzheimer's Disease, for instance:
• May be getting lost in familiar places
• May become confused while preforming previously routine tasks
• New or worsening challenges with language, writing, math, or drawing
• Decision making may be difficult, or errors in decision making are new
• Other may notice words, phrases, or questions are repeated
• Generally healthy enough to participate in all study activities and travel
• Have shown an important decline in memory and daily functions from a previous higher level of ability
• Cause of Memory loss is not due to stroke, cardiovascular, or other non-Alzheimer's causes
• No episodes of violence or aggression
• Not taking insulin
• Has never been diagnosed with breast cancer

To Get Involved today, email: bioviepharma.com

Other Research Trials in New York City

NYU Langone Health

The NYU Langone Vaccine Center is seeking healthy adult volunteers who are interested in participating in clinical research for a COVID-19 vaccine study.

LEAF: Life Enhancing Activities for Family Caregivers

Do you care for someone with Alzheimer's Disease?
Many family caregivers of people with Alzheimer's Disease experience physical and emotional changes as a result of their caregiving. Research shows that increasing one’s levels of positive emotion can lower stress and increase the ability to cope with existing stress. We are interested in the effects of applying these techniques with Alzheimer's family caregivers.

Who is eligible to participate?
If you are the primary caregiver of a person diagnosed with Alzheimer's Disease
and have access to a reliable Wi-Fi internet connection, you may be eligible!

Participating in the LEAF study involves:
Taking part in a positive emotions building study program via:

• Six (6) weekly hour-long video sessions with a facilitator OR a
  6-week self-guided online program (you would be randomly chosen for video sessions or the online program)
• Nightly home practice to reinforce the skills
• Online surveys

Visit us at: http://leafstudy.ucsf.edu and fill out our eligibility survey
Email us at: LEAFstudy@northwestern.edu
Call us at: 312-503-5247 (Central time)

New Clinical Study Currently Enrolling People with Memory Loss and Elevated Blood Sugar

The Elevage study (NCT03980730) is being conducted to evaluate the efficacy and safety of azeliragon in patients who are experiencing memory loss and have elevated blood sugar or Type 2 Diabetes.

To qualify for participation in the study you must:

• Be 50-85 years of age (inclusive)
• Currently be taking medication for memory loss (including Aricept (donepezil), Exelon (rivastigmine), Razadyne or Reminyl (galantamine) and/or Namenda or Ebixa (memantine), etc.)
• Have elevated blood sugar (A1c 6.5% to 9.5%)
• Have a reliable caregiver/study partner

To learn more, click here.

Join a Research Study: Neurodegeneration-Associated Psychiatric Syndromes

Principal Investigator: Edward Huey, M.D.
Seeking participants for an observational research study looking at how dementias (like Alzheimer’s disease) can affect mood and behavior.

• Participation involves coming in with a study partner (someone who knows you well) for one voluntary, 4-5 hour visit to answer questions about recent mood and emotions and complete an MRI scan
• Participants will be compensated $50-$100

This study is recruiting participants with dementia, including:

• People who have been diagnosed with Alzheimer’s disease
• Who are between 40-90 years old,
• And who speak English or Spanish.

How do I participate?
If you are interested in becoming involved in this study or learning more, please contact the research team at (212) 305-3187 or HueyResearchTeam@cumc.columbia.edu

Weill Cornell Medicine - Family Caregiver Research Study

Do you care for someone with dementia and pain? Are you a family member or unpaid caregiver?

If so, we want to learn from you! You are invited to participate in a one-time, 20-30 minute in person or phone interview. To thank you for your time, you will be provided with a $15 gift card after completing the interview.

For more information or to participate, please contact Dr. Riffin: 212-746-7317 or acr2213@med.cornell.edu

Care Partners Program

If you are caring for a loved one with Alzheimer’s or other dementias, you might be eligible to take part in a research study that Weill Cornell Medicine is conducting. You will learn strategies to reduce stress, enhance caregiving skills, and improve overall well-being. Your loved one will receive cognitive training or mental stimulating exercises.

The study has a duration of 12 months. You and your loved one can participate from the comfort of your home at no cost. You will receive a laptop with Wi-fi capability during study participation to access study-related material and content. You will also receive financial compensation for your time and effort.

For more information, please contact us at:
(646) 962-7141 or AgingBehavioralRsrch@med.cornell.edu

Seeking individuals with Alzheimer’s disease who experience agitation

The Escitalopram for Agitation in Alzheimer’s Disease (S-CitAD) study is a 12-week trial of escitalopram taking place at Memory Disorders Clinic at New York State Psychiatric Institute.

The S-CitAD Research Study is looking for volunteers who:

• Have been diagnosed with Alzheimer’s disease
• Experience feelings of irritability, restlessness, frustration, or anger
• Have a study partner who can participate in the study

All participants receive: Free parking at each visit, Psychosocial counseling provided to all eligible participants, All visit procedures administered at no cost.

Call 646-774-8671 for more information.

Survey for Caregivers

Are you currently providing care to someone with dementia? Are you employed or were you employed at any point while caring for your friend, family member, or neighbor with Alzheimer’s disease or Dementia? If you answered ‘yes’, then we would love to hear from you!

Researchers at the University at Albany School of Public Health are looking for interested individuals to participate in a study that seeks to understand the experiences of working caregivers. This anonymous survey should take about 10-15 minutes of your time, and can be accessed at the following link:

https://www.surveymonkey.com/r/WorkandCaregiving

Participate in a research project on Alzheimer's and Caregiving

The purpose of this project is to identity the types of decisions that caregivers face as their family member or friend progresses through the stages of Alzheimer's.

Learn more

Cognite Early Stage Alzheimer's Clinical Trial

Imagine making an impact

Consider taking part in a clinical trial that is currently enrolling to treat for early stage Alzheimer’s disease

What is the Cognite Trial?

The Cognite Alzheimer’s Clinical Trial is enrolling men and women who have signs of early stage Alzheimer’s disease. The clinical trial is evaluating whether an investigational combined treatment slows down, arrests, or reverses early stage Alzheimer’s disease.

To qualify, participants must:

• Be between 55 and 79 years old
• Have at least 8 years of education
• Have noticed, or have had a loved one notice, changes in your memory
• Have noticed changes in their normal, everyday behavior
• Attend all study visits with a study partner with whom the
  participant has frequent contact
• Be in good general health

Are you or someone you know experiencing memory loss? Are you or someone you know having trouble retaining information? This may be an indication of early stage Alzheimer’s disease, which is a type of dementia that causes problems with an individual’s memory, thinking, and behavior.

For more information:

646-678-4196 | cognitetrial.com

Learn more (PDF)

Treatment of Psychosis and Agitation in Alzheimer’s Disease

This research study, funded by the NIH, involves a 12-week double-blind treatment trial in which outpatients with Alzheimer’s disease (age 55-95 years) who have agitation/aggression with or without psychosis (hallucinations or delusions) will receive either low-dose lithium or placebo. Patients are allowed to receive other specific psychiatric medications if needed during the study, and will be closely monitored by physicians who specialize in memory disorders. Patients will receive open treatment with lithium, if clinically indicated, after completing the 12-week double blind trial.
For more information, please contact Jesse Strickler at (646) 774-8668 or strickl@nyspi.columbia.edu.
ClinicalTrials.gov Identifier: NCT02129348